HC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)
HC Wainwright reiterated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $110.00 target price on the stock. Several other research firms have also issued reports on VIR. Barclays lowered their target price on shares of […]
More Stories
Pentair plc (NYSE:PNR) Shares Bought by Swedbank AB
Swedbank AB grew its stake in shares of Pentair plc (NYSE:PNR – Free Report) by 17.9% in the third quarter,...
iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ) Stock Position Trimmed by Wescott Financial Advisory Group LLC
Wescott Financial Advisory Group LLC cut its position in iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ – Free Report) by...
The PMI Group (OTCMKTS:PPMIQ) and NMI (NASDAQ:NMIH) Head to Head Comparison
NMI (NASDAQ:NMIH – Get Free Report) and The PMI Group (OTCMKTS:PPMIQ – Get Free Report) are both finance companies, but...
Penserra Capital Management LLC Boosts Stake in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY)
Penserra Capital Management LLC lifted its position in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY – Free Report) by...
Pfizer (NYSE:PFE) Stock Acquired Rep. Laurel M. Lee
Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the...
Wescott Financial Advisory Group LLC Trims Stock Holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)
Wescott Financial Advisory Group LLC decreased its holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA – Free Report) by 1.2%...